Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Mohammad Yaseen Abbasi, Weerachai Chaijamorn, Kamonthip Wiwattanawongsa, Taniya Charoensareerat, Thitima Doungngern
{"title":"Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.","authors":"Mohammad Yaseen Abbasi,&nbsp;Weerachai Chaijamorn,&nbsp;Kamonthip Wiwattanawongsa,&nbsp;Taniya Charoensareerat,&nbsp;Thitima Doungngern","doi":"10.2147/CPAA.S417298","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In addition to the maximum plasma concentration (C<sub>max</sub>) to the minimum inhibitory concentration (MIC) ratio, the 24-hour area under the concentration-time curve (AUC<sub>24h</sub>) to MIC has recently been suggested as pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy and safety in once-daily dosing of gentamicin (ODDG) in critically ill patients.</p><p><strong>Purpose: </strong>This study aimed to predict the optimal effective dose and risk of nephrotoxicity for gentamicin in critically ill patients for two different PK/PD targets within the first 3 days of infection.</p><p><strong>Methods: </strong>The gathered pharmacokinetic and demographic data in critically ill patients from 21 previously published studies were used to build a one-compartment pharmacokinetic model. The Monte Carlo Simulation (MCS) method was conducted with the use of gentamicin once-daily dosing ranging from 5-10 mg/kg. The percentage target attainment (PTA) for efficacy, C<sub>max</sub>/MIC ~8-10 and AUC<sub>24h</sub>/MIC ≥110 targets, were studied. The AUC<sub>24h</sub> >700 mg⋅h/L and C<sub>min</sub> >2 mg/L were used to predict the risk of nephrotoxicity.</p><p><strong>Results: </strong>Gentamicin 7 mg/kg/day could achieve both efficacy targets for more than 90% when the MIC was <0.5 mg/L. When the MIC increased to 1 mg/L, gentamicin 8 mg/kg/day could reach the PK/PD and safety targets. However, for pathogens with MIC ≥2 mg/L, no studied gentamicin doses were sufficient to reach the efficacy target. The risk of nephrotoxicity using AUC<sub>24h</sub> >700 mg⋅h/L was small, but the risk was greater when applying a C<sub>min</sub> target >2 mg/L.</p><p><strong>Conclusion: </strong>Considering both targets of Cmax/MIC ~8-10 and AUC<sub>24h</sub>/MIC ≥110, an initial gentamicin dose of 8 mg/kg/day should be recommended in critically ill patients for pathogens with MIC of ≤1 mg/L. Clinical validation of our results is essential.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"15 ","pages":"67-76"},"PeriodicalIF":3.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/84/cpaa-15-67.PMC10329437.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S417298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: In addition to the maximum plasma concentration (Cmax) to the minimum inhibitory concentration (MIC) ratio, the 24-hour area under the concentration-time curve (AUC24h) to MIC has recently been suggested as pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy and safety in once-daily dosing of gentamicin (ODDG) in critically ill patients.

Purpose: This study aimed to predict the optimal effective dose and risk of nephrotoxicity for gentamicin in critically ill patients for two different PK/PD targets within the first 3 days of infection.

Methods: The gathered pharmacokinetic and demographic data in critically ill patients from 21 previously published studies were used to build a one-compartment pharmacokinetic model. The Monte Carlo Simulation (MCS) method was conducted with the use of gentamicin once-daily dosing ranging from 5-10 mg/kg. The percentage target attainment (PTA) for efficacy, Cmax/MIC ~8-10 and AUC24h/MIC ≥110 targets, were studied. The AUC24h >700 mg⋅h/L and Cmin >2 mg/L were used to predict the risk of nephrotoxicity.

Results: Gentamicin 7 mg/kg/day could achieve both efficacy targets for more than 90% when the MIC was <0.5 mg/L. When the MIC increased to 1 mg/L, gentamicin 8 mg/kg/day could reach the PK/PD and safety targets. However, for pathogens with MIC ≥2 mg/L, no studied gentamicin doses were sufficient to reach the efficacy target. The risk of nephrotoxicity using AUC24h >700 mg⋅h/L was small, but the risk was greater when applying a Cmin target >2 mg/L.

Conclusion: Considering both targets of Cmax/MIC ~8-10 and AUC24h/MIC ≥110, an initial gentamicin dose of 8 mg/kg/day should be recommended in critically ill patients for pathogens with MIC of ≤1 mg/L. Clinical validation of our results is essential.

Abstract Image

Abstract Image

基于不同药代动力学/药效学目标的成人重症监护患者庆大霉素剂量推荐:一种重新定义的方法。
背景:除了最大血浆浓度(Cmax)与最小抑制浓度(MIC)之比外,最近有研究建议将24小时浓度-时间曲线下面积(AUC24h)与MIC之比作为危重患者每日一次给药庆大霉素(ODDG)有效性和安全性的药代动力学/药效学(PK/PD)指标。目的:本研究旨在预测两种不同PK/PD靶点的危重患者在感染前3天内庆大霉素的最佳有效剂量和肾毒性风险。方法:收集21篇已发表的危重患者的药代动力学和人口学资料,建立单室药代动力学模型。采用蒙特卡洛模拟(Monte Carlo Simulation, MCS)方法,使用庆大霉素每日一次给药,剂量范围为5-10 mg/kg。观察疗效指标达成百分比(PTA), Cmax/MIC≥8 ~ 10,AUC24h/MIC≥110。以AUC24h >700 mg⋅h/L和Cmin >2 mg/L预测肾毒性风险。结果:庆大霉素7 mg/kg/d在MIC为24h时可达到90%以上的疗效目标,>700 mg·h/L较低,但应用Cmin目标>2 mg/L时风险较大。结论:考虑Cmax/MIC ~8 ~ 10和AUC24h/MIC≥110两项指标,对于MIC≤1mg /L的危重患者,应推荐庆大霉素初始剂量8mg /kg/d。临床验证我们的结果是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
14
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信